REGENXBIO (NASDAQ:RGNX) Lowered to "Neutral" Rating by The Goldman Sachs Group

REGENXBIO (NASDAQ:RGNX - Get Free Report) was downgraded by stock analysts at The Goldman Sachs Group from a "buy" rating to a "neutral" rating in a report issued on Tuesday, MarketBeat Ratings reports. They presently have a $14.00 price target on the biotechnology company's stock, down from their previous price target of $38.00. The Goldman Sachs Group's target price suggests a potential upside of 89.83% from the company's current price.

Other equities analysts have also recently issued reports about the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $30.00 target price on shares of REGENXBIO in a report on Tuesday, January 21st. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 target price on shares of REGENXBIO in a report on Wednesday, January 15th. Chardan Capital reaffirmed a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a report on Wednesday, November 20th. Morgan Stanley reiterated an "overweight" rating and issued a $22.00 price objective on shares of REGENXBIO in a research report on Friday, November 15th. Finally, Raymond James initiated coverage on shares of REGENXBIO in a research report on Friday, February 7th. They issued an "outperform" rating and a $27.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $33.45.

REGENXBIO Trading Up 0.8 %

Shares of REGENXBIO stock traded up $0.06 during trading on Tuesday, reaching $7.38. The company's stock had a trading volume of 341,210 shares, compared to its average volume of 989,830. The company has a 50-day moving average price of $7.96 and a two-hundred day moving average price of $9.91. The firm has a market cap of $365.36 million, a PE ratio of -1.47 and a beta of 1.29. REGENXBIO has a fifty-two week low of $6.56 and a fifty-two week high of $28.80.

Institutional Investors Weigh In On REGENXBIO

Institutional investors have recently made changes to their positions in the stock. Barclays PLC boosted its position in shares of REGENXBIO by 141.3% during the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company's stock worth $1,217,000 after purchasing an additional 67,948 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock worth $6,621,000 after purchasing an additional 296,700 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of REGENXBIO by 602.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company's stock worth $214,000 after purchasing an additional 17,533 shares in the last quarter. FMR LLC boosted its position in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 1,656 shares in the last quarter. Finally, Stifel Financial Corp boosted its position in shares of REGENXBIO by 13.3% during the 3rd quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company's stock worth $1,566,000 after purchasing an additional 17,563 shares in the last quarter. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.